Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Up 4.9%

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report)'s stock price traded up 4.9% on Monday . The stock traded as high as $29.42 and last traded at $29.26. 90,288 shares were traded during trading, a decline of 87% from the average session volume of 699,426 shares. The stock had previously closed at $27.88.

Analysts Set New Price Targets

Several brokerages recently commented on TARS. HC Wainwright boosted their price target on shares of Tarsus Pharmaceuticals from $57.00 to $61.00 and gave the stock a "buy" rating in a report on Monday, May 13th. Barclays boosted their price target on shares of Tarsus Pharmaceuticals from $50.00 to $60.00 and gave the stock an "overweight" rating in a report on Friday, May 10th. Finally, Oppenheimer boosted their price target on shares of Tarsus Pharmaceuticals from $59.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 9th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $50.38.

Tarsus Pharmaceuticals Stock Performance

The stock has a market capitalization of $1.07 billion, a PE ratio of -5.93 and a beta of 1.05. The firm's fifty day moving average is $32.54 and its 200-day moving average is $30.81. The company has a current ratio of 8.01, a quick ratio of 7.92 and a debt-to-equity ratio of 0.11.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.14. The company had revenue of $27.61 million during the quarter, compared to analysts' expectations of $17.94 million. As a group, research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.75 earnings per share for the current year.

Institutional Trading of Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Swiss National Bank increased its stake in Tarsus Pharmaceuticals by 1.4% during the first quarter. Swiss National Bank now owns 42,433 shares of the company's stock worth $1,542,000 after purchasing an additional 600 shares during the period. Tower Research Capital LLC TRC increased its stake in Tarsus Pharmaceuticals by 22.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,560 shares of the company's stock worth $92,000 after purchasing an additional 824 shares during the period. Callan Capital LLC increased its stake in shares of Tarsus Pharmaceuticals by 11.5% during the fourth quarter. Callan Capital LLC now owns 16,950 shares of the company's stock worth $343,000 after buying an additional 1,750 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of Tarsus Pharmaceuticals by 11.5% during the fourth quarter. Janney Montgomery Scott LLC now owns 24,227 shares of the company's stock worth $491,000 after buying an additional 2,500 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Tarsus Pharmaceuticals by 71.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 6,567 shares of the company's stock worth $239,000 after buying an additional 2,735 shares during the period. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.